However, in advanced CML, neoplastic cells may even be resistant against ponatinib or asciminib, especially when these cells exhibit complex molecular aberration‐patterns or BCR::ABL1 compound mutations.23, 24, 25. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.